283 reports of this reaction
3.3% of all REGADENOSON reports
#7 most reported adverse reaction
CARDIAC ARREST is the #7 most commonly reported adverse reaction for REGADENOSON, manufactured by Astellas Pharma US, Inc.. There are 283 FDA adverse event reports linking REGADENOSON to CARDIAC ARREST. This represents approximately 3.3% of all 8,610 adverse event reports for this drug.
Patients taking REGADENOSON who experience cardiac arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC ARREST is moderately reported among REGADENOSON users, representing a notable but not dominant share of adverse events.
In addition to cardiac arrest, the following adverse reactions have been reported for REGADENOSON:
The following drugs have also been linked to cardiac arrest in FDA adverse event reports:
CARDIAC ARREST has been reported as an adverse event in 283 FDA reports for REGADENOSON. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC ARREST accounts for approximately 3.3% of all adverse event reports for REGADENOSON, making it a notable side effect.
If you experience cardiac arrest while taking REGADENOSON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.